Clinical and microbiologic efficacy and safety profile of linezolid, a new oxazolidinone antibiotic (Q44238452)

1 December 2017

Clinical and microbiologic efficacy and safety profile of linezolid, a new oxazolidinone antibiotic (English)

1 reference

1 December 2017

1 reference

Corti G

1

1 reference

PubMed ID

11118873

1 December 2017

Cinelli R

series ordinal

2

1 reference

PubMed ID

11118873

1 December 2017

Paradisi F

series ordinal

3

1 reference

1 December 2017

1 December 2000

1 reference

International Journal of Antimicrobial Agents

1 December 2017

1 reference

1 December 2017

16

1 reference

1 December 2017

4

1 reference

1 December 2017

527-530

1 reference

Major trends in the microbial etiology of nosocomial infection.

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900290-9

7 January 2021

Predominant pathogens in hospital infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900290-9

7 January 2021

Spread of vancomycin-resistant enterococci: why did it happen in the United States?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900290-9

7 January 2021

“Celbenin” - resistant Staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900290-9

7 January 2021

Nosocomial bloodstream infections in United States hospitals: a three-year analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900290-9

7 January 2021

Methicillin-resistant Staphylococcus aureus in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900290-9

7 January 2021

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900290-9

7 January 2021

Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900290-9

7 January 2021

Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900290-9

7 January 2021

Increased resistance among Staphylococcus epidermidis isolates in a large teaching hospital over a 12-year period

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900290-9

7 January 2021

Emergence of Multiply Resistant Pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900290-9

7 January 2021

Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900290-9

7 January 2021

The in-vitro activity of linezolid (U-100766) and tentative breakpoints

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900290-9

7 January 2021

In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900290-9

7 January 2021

In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900290-9

7 January 2021

Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900290-9

7 January 2021

Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxa

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900290-9

7 January 2021

Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900290-9

7 January 2021

10.1016/S0924-8579(00)00290-9

Identifiers

DOI

1 reference

1 December 2017

1 reference

PubMed ID

11118873